Animal Behavior Webinar Series Begins March 31March 8, 2011ImproMed LLC, a subsidiary of Butler Schein Animal Health, will host a three-part webinar series on animal behavior as it pertains to the veterinary examination on Thursday, March 31, Thursday, April 7 and Thursday, April 14 at 1 p.m. CST. Sally Foote, DVM, a general practice veterinarian and veterinary behavioral consultant, will be the presenter. The first session, “Putting Your Patient First,” will include an overview of restraint techniques and physical restriction, newer non-force techniques, the importance of staff safety and client acceptance and step-by-step techniques for the front office staff, technicians and veterinarians. The second session, “Consistency Is Key Documentation and Score,” will focus on the importance of documenting the reinforcers or rewards for that particular patient. The benefits of documentation will also be discussed. “Polishing Up Positive Reinforcement Techniques for Veterinarians,” will be the final session. It will detail positive reinforcement during the veterinary exam, including different factors that affect the response of the animal to the handler and veterinarian. Emphasis during this webinar will be put on the development of observing more subtle body language cues from dogs and cats. Attendees can earn three continuing education credits. For webinar details, click here.
SPONSORED CONTENTA Modern Approach to Parasite PreventionWith evolving parasite threats, traditional preventatives may not be enough. Discover how innovation is changing the landscape of protection. + Learn More
South Korea Gets 12 Million Vaccines To Combat FMD OutbreakMarch 7, 2011 Intervet/Schering-Plough Animal Health in early March delivered 12 million doses of its foot-and-mouth disease (FMD) vaccine to South Korea in an effort to halt the country’s FMD outbreak. The South Korean government reported the FMD outbreak in November 2010. Since then, more than three million pigs, cattle, goats and deer have been culled. The South Korean Ministry for Food, Agriculture, Forestry and Fisheries has since started vaccinating all 13 million livestock in the country after initial measures were not effective in controlling the outbreak. It is anticipated that the ongoing vaccination campaign will soon show results in the control of the outbreak in concert with the other measures applied, according to Intervet/Schering-Plough Animal Health, a subsidiary of Merck & Co. Inc. of Whitehouse Station, N.J. The 12 million doses of Decivac FMD DOE, an inactivated oil-adjuvanted vaccine, were produced at the company’s production facility in Germany. <Home>
Ohio State Veterinarian Named Vet Of The YearMarch 4, 2011 The Ohio State Veterinarian received the award for his outstanding contributions, dedication and service to the veterinary profession, the community and animals. “He has served the animal kingdom, the general public and his colleagues by giving an active voice to the veterinarians of Ohio,” said OVMA President Jason Johnston, DVM, during the awards ceremony at the OVMA’s annual Midwest Veterinary Conference in late February. “Through his knowledge, compassion and dedication to the profession, he has strived to ensure that only the highest standards of veterinary medicine are practiced in Ohio.” Dr. George Kukor (right) receives the Distinguished Service Award, presented by Dr. Johnston. Among other accomplishments, Dr. Forshey took on the task of shepherding the work of the newly formed Ohio Livestock Care Standards Board in 2010. It is a role that has been critical in advancing fair, humane standards, Dr. Johnston said. The OVMA also recognized George Kukor, DVM, for his contributions to the profession with the Distinguished Service Award. The award recognizes an individual for exemplary service, commitment and dedication to the veterinary community. “During his career, he has never stopped giving back to the profession he loves,” Johnston …
Aratana Gets Rights To Two Compounds For Animal UseMarch 4, 2011 Aratana Therapeutics Inc. of Kansas City, Kan., reported today that it has entered into a license agreement with RaQualia Pharma Inc. to develop two compounds from RaQualia’s human clinical development portfolio for companion animal use. As part of the agreement, Aratana will be granted global rights for development and commercialization of the licensed animal health products. In exchange, the Japanese company will receive upfront payment, development milestones and royalties on global sales. The first compound is a selective EP-4 antagonist. Aratana reported that the compound has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for several conditions including, pain, cancer and autoimmune/inflammatory diseases. The second compound, a selective Ghrelin agonist, has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for treatment of cachexia and frailty, according to Aratana. Aratana announced its entry into the animal health industry in early January, which was jump-started by $20 million in Series A financing. Related story: Aratana Enters Animal Health Industry with $20 Million in Funding <Home>
Western Veterinary Conference Sees Record AttendanceMarch 3, 2011 More than 14,600 people attended the 83rd Annual Western Veterinary Conference last month in Las Vegas, an attendance record. Last year, the total was about 13,500. More than 14,600 people attended the 83rd Annual Western Veterinary Conference last month in Las Vegas, an attendance record. Last year, the total was about 13,500. newsline More than 14,600 people attended the 83rd Annual Western Veterinary Conference in February in Las Vegas, an attendance record. Last year, the total was about 13,500. This year’s attendance included 6,220 veterinarians; 1,513 veterinary technicians; 330 practice managers; 1,381 guests; 246 administrative staff; 145 DVM students; 387 veterinary technician students; 3,719 exhibitor representatives; 322 general attendee/press; and 354 vendor and support staff. The conference offered more than 875 hours of continuing education, about 30 hands-on laboratories and workshops, more than 30 focused symposia, 18 industry seminars and a “hugely expanded” exhibit hall. The exhibit hall, located upstairs this year on Level 2, was increased by 65 percent, according to Manolita Moore, annual conference director. WVC added nearly 100 more exhibitors in 2011 for a total of 550. “By introducing the Hall’s Grand Pavilion for easy access to exhibitor information plus our …
Georgia Considers Adding State Tax To Vet ServicesMarch 2, 2011 Georgia pet owners could see their veterinary bills increase by an overall 7 percent to 8 percent due to taxation if a proposed pet tax becomes law. House Bills 385-388 all include language that will tax “veterinarian expenses for pets,” among other services. Although medications and supplies are already taxed, veterinary services are not. The Georgia Veterinary Medical Association sent out a media alert today asking veterinarians and pet owners to contact their legislator and ask them to oppose any effort to impose a tax on veterinary services. Veterinarians are the only health care group targeted, the GVMA pointed out. “No other professionals are being targeted by this legislation,” GVMA said in its media alert. “Nor are any other health care professionals, who are also service providers, finding their practices threatened. Medical services have long been exempt from taxation at the state and federal level.” According to GVMA, adding a sales tax to veterinary services may force owners to: forego life-saving procedures and opt for economic euthanasia; have a substantial financial impact on responsible veterinary care of pets; and increase pet abandonment. This tax tactic has been attempted in other states—California, Maine, Michigan …
VetDC Acquires Veterinary Rights For Cancer MoleculeMarch 2, 2011 VetDC Inc. reported today that it has acquired North American veterinary rights to Gilead Sciences Inc.’s investigational molecule, GS 9219, for use in animal cancer. VetDC is a Colorado State University startup based in Fort Collins, Colo. The product development company focuses on in-licensing, developing and commercializing human biomedical technologies for use in dogs and cats. “This deal demonstrates VetDC’s capabilities in partnering with leading biotechnology companies, like Gilead, to acquire novel technologies for development and commercialization in companion animal settings,” said Steven Roy, president and CEO of VetDC. “The transaction with Gilead is a major milestone in our ongoing efforts to license innovative products and intellectual properties that will advance veterinary medicine.” GS 9219, as described by VetDC, is an anti-proliferative agent that preferentially targets lymphoid cells and works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death. An intravenous version of GS 9219 was evaluated for the treatment of canine lymphoma in a recently completed animal study. The product was well tolerated and demonstrated significant activity against spontaneous non-Hodgkin’s lymphoma in pet dog subjects (n=38), according to VetDC. These results suggest GS 9219 could be …
AMC Names New Chief Of SurgeryFebruary 28, 2011The Animal Medical Center in New York City has named Roger Avery Bennett, Jr., DVM, Dipl. ACVS, as chief of surgery. “As we move forward into a promising second century, Dr. Bennett’s diverse, extensive experience in veterinary surgery will be instrumental in furthering The AMC’s core mission of advancing veterinary medicine and pioneering effective therapies,” said Kathryn Coyne, AMC’s CEO. “With more than 20 years of surgical proficiency across various platforms in veterinary medicine, coupled with his depth of knowledge and surgical skills, I am confident Dr. Bennett will be an enormous asset to The AMC.” Prior, Bennett was a professor of small animal surgery at the College of Veterinary Medicine, Department of Veterinary Medicine in Urbana, Ill., with appointments in soft tissue, oncologic, orthopedic and neurologic surgery. He also served as clinical associate professor of small animal surgery at the University of Pennsylvania School of Veterinary Medicine and held positions in zoo and wildlife medicine, including chief veterinarian at The San Francisco Zoological Gardens and associate professor of Zoo and Wildlife Medicine at the Department of Small Animal Clinical Sciences, University of Florida College of Veterinary Medicine. “It is truly a privilege to join The AMC, a national leader …
Stem Cell Conference Scheduled For Early JuneFebruary 25, 2011 The North American Veterinary Regenerative Medicine Association will be holding a conference on stem cell therapy and regenerative medicine on June 2-5 in Lexington, Ky. About 400 people are expected to attend, including veterinarians, research scientists and medical professionals. The conference will feature scientific presentations and discussion sessions that blend research and practical applications, addressing all aspects of stem cell therapy and regenerative medicine in horses and small animals, according to the University of California, Davis School of Veterinary Medicine. The association was formed by the vet school, among others, in 2010 as a way to promote research and sharing of new findings related to regenerative medicine and stem cell therapy in animals. The vet school is joining with horse clinics in Kentucky and California to coordinate the conference. A special half-day forum is planned for horse owners, trainers and equine professionals on June 4. For details, visit the group's website. <Home>
Raccoon Rabies Eliminated In Two New York CountiesFebruary 24, 2011 Rabies in raccoons has been officially eliminated in two New York counties, Cornell University reported today. The success story in Nassau and Suffolk counties, part of New York’s Long Island, is being attributed to Cornell’s Wildlife Oral Rabies Vaccination Program. The program was initiated during the mid-1990s. The World Health Organization defines such success as a lack of rabies cases after two years of enhanced surveillance, according to Laura Bigler, Ph.D., a Cornell wildlife biologist and program coordinator. The last raccoon rabies case in Nassau County was in November 2007. Suffolk County’s last case was in January 2009. Cornell’s program uses a U.S. Department of Agriculture-licensed liquid rabies vaccine hidden inside a small sachet that is coated with fishmeal and fish oil. Raccoons are attracted to the bait by its fishy smell, according to the university. The raccoons puncture the baits and ingest the liquid vaccine. Cornell took over managing rabies-control efforts in Nassau and Suffolk counties in 2006. Since then, about 372,000 baits per year have been distributed, targeting populated suburban neighborhoods either via GIS-satellite-guided helicopter drops, vehicle tosses or bait stations that were developed at Cornell. “In 2004, the New …
